Trial Profile
Cardiodynamic trial of Piclidenoson (CF101) in healthy volunteer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2017
Price :
$35
*
At a glance
- Drugs Piclidenoson (Primary)
- Indications Glaucoma; Osteoarthritis; Plaque psoriasis; Rheumatoid arthritis; Uveitis
- Focus Adverse reactions
- 11 Aug 2017 New trial record
- 07 Aug 2017 According to a Can-Fite BioPharma media release, in this study, piclidenoson doses were up to 3-fold higher than the highest dose expected to be used in the registration-directed clinical trials
- 07 Aug 2017 According to a Can-Fite BioPharma media release, this trial is a regulatory safety requirement of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) prior to the initiation of Phase III studies.